

Ziad A Massy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/369187/publications.pdf>

Version: 2024-02-01

271
papers

16,525
citations

25034

57
h-index

18130

120
g-index

275
all docs

275
docs citations

275
times ranked

17195
citing authors

#	ARTICLE	IF	CITATIONS
1	Urea levels and cardiovascular disease in patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 184-192.	0.7	9
2	The Role of Uremic Retention Solutes in the MIA Syndrome in Hemodialysis Subjects. <i>Blood Purification</i> , 2023, 52, 41-53.	1.8	2
3	Patient-reported factors influencing the choice of their kidney replacement treatment modality. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 477-488.	0.7	18
4	Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial. <i>Clinical Research in Cardiology</i> , 2022, 111, 614-626.	3.3	8
5	Running interference: lumasiran and other RNA interference therapeutics for kidney diseases. <i>Kidney International</i> , 2022, 101, 208-211.	5.2	3
6	A Predictive Model for Progression of CKD to Kidney Failure Based on Routine Laboratory Tests. <i>American Journal of Kidney Diseases</i> , 2022, 79, 217-230.e1.	1.9	21
7	New insights into acute-on-chronic kidney disease in nephrology patients: the CKD-REIN study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1700-1709.	0.7	7
8	Work status and work ability of patients receiving kidney replacement therapy: results from a European survey. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2022-2033.	0.7	7
9	Incidence of Kidney Replacement Therapy and Subsequent Outcomes Among Patients With Systemic Lupus Erythematosus: Findings From the ERA Registry. <i>American Journal of Kidney Diseases</i> , 2022, 79, 635-645.	1.9	3
10	Prevalence of familial hypercholesterolaemia in patients presenting with premature acute coronary syndrome. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 87-95.	1.6	5
11	Role of uremic toxins in vascular disease—“the end of nihilism?”. <i>Kidney International</i> , 2022, 101, 1100-1102.	5.2	2
12	Sortilin, carbamylation, and cardiovascular calcification in chronic kidney disease. <i>Kidney International</i> , 2022, 101, 456-459.	5.2	3
13	Association of Serum Phosphate with Efficacy of Statin Therapy in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 546-554.	4.5	7
14	The relationship between uremic toxins and symptoms in older men and women with advanced chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 798-807.	2.9	5
15	High cholesterol absorption is associated with increased cardiovascular risk in haemodialysis patients: insights from the AURORA study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1731-1739.	1.8	3
16	Low turnover bone disease in early CKD stages. <i>Kidney International Reports</i> , 2022, , .	0.8	1
17	Uremic Toxins and Cardiovascular Risk in Chronic Kidney Disease: What Have We Learned Recently beyond the Past Findings?. <i>Toxins</i> , 2022, 14, 280.	3.4	20
18	MO503: Cognitive Performance in Patients With Chronic Kidney Disease: Results From the CKD-Rein Cohort Study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0

#	ARTICLE	IF	CITATIONS
19	MO499: Incidence of Cause-Specific Cardiovascular Events in Men and Women With CKD. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
20	Less arterial stiffness in kidney transplant recipients than chronic kidney disease patients matched for renal function. CKJ: Clinical Kidney Journal, 2021, 14, 1244-1254.	2.9	6
21	Dietâ€™microbiota interaction and kidney disease progression. Kidney International, 2021, 99, 797-800.	5.2	4
22	The association of living donor source with patient and graft survival among kidney transplant recipients in the ERAâ€™EDTA Registry â€™ a retrospective study. Transplant International, 2021, 34, 76-86.	1.6	2
23	Long- Versus Short-Acting Erythropoiesis-Stimulating Agent Type and Mortality. Kidney International Reports, 2021, 6, 214-218.	0.8	6
24	Serum total indoxyl sulfate and clinical outcomes in hemodialysis patients: results from the Japan Dialysis Outcomes and Practice Patterns Study. CKJ: Clinical Kidney Journal, 2021, 14, 1236-1243.	2.9	18
25	Non-medical barriers reported by nephrologists when providing renal replacement therapy or comprehensive conservative management to end-stage kidney disease patients: a systematic review. Nephrology Dialysis Transplantation, 2021, 36, 848-862.	0.7	20
26	A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: a multinational analysis of CKDopps. Scientific Reports, 2021, 11, 1784.	3.3	23
27	Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?. Nephrology Dialysis Transplantation, 2021, 37, ii33-ii44.	0.7	26
28	Intestinal Chelators, Sorbants, and Gut-Derived Uremic Toxins. Toxins, 2021, 13, 91.	3.4	10
29	Hyponatremia under MAP kinase inhibitors: a complex relationship between aquaporins and ERK activation. Kidney International, 2021, 99, 488.	5.2	0
30	Effect of comorbidities on survival in patients >80â€™years of age at onset of renal replacement therapy: data from the ERA-EDTA Registry. Nephrology Dialysis Transplantation, 2021, 36, 688-694.	0.7	4
31	The spectrum of kidney biopsies in hospitalized patients with COVID-19, acute kidney injury and/or proteinuria. Nephrology Dialysis Transplantation, 2021, 36, 1253-1262.	0.7	54
32	Temporal trends in the quality of deceased donor kidneys and kidney transplant outcomes in Europe: an analysis by the ERA-EDTA Registry. Nephrology Dialysis Transplantation, 2021, 37, 175-186.	0.7	11
33	The evolving science of anemia management in chronic kidney disease. Kidney International Supplements, 2021, 11, 1-2.	14.2	2
34	Metformin prevents stroke damage in non-diabetic female mice with chronic kidney disease. Scientific Reports, 2021, 11, 7464.	3.3	8
35	MO484ADVERSE OUTCOMES ASSOCIATED WITH ORAL ANTITHROMBOTIC USE IN PATIENTS WITH MODERATE-TO-ADVANCED CHRONIC KIDNEY DISEASE*. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
36	MO496PRESCRIPTION OF DIRECT ORAL ANTICOAGULANTS TO PATIENTS WITH MODERATE TO ADVANCED CKD : TOO LITTLE OR JUST RIGHT?. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0

#	ARTICLE	IF	CITATIONS
37	Urgent-start dialysis in patients referred early to a nephrologist—the CKD-REIN prospective cohort study. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1500-1510.	0.7	4
38	Phosphate meeting cholesterol—consequences for cardiovascular disease in chronic kidney disease?. <i>Kidney International</i> , 2021, 99, 1264-1267.	5.2	2
39	Effect of Sevelamer and Nicotinamide on Albumin Carbamylation in Patients with End-Stage Kidney Disease. <i>Drugs in R and D</i> , 2021, 21, 231-238.	2.2	3
40	Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. <i>Kidney International</i> , 2021, 99, 1280-1295.	5.2	103
41	Why and how should we promote home dialysis for patients with end-stage kidney disease during and after the coronavirus 2019 disease pandemic? A French perspective. <i>Journal of Nephrology</i> , 2021, 34, 985-989.	2.0	11
42	Renin-Angiotensin System Blockers and the Risk of COVID-19—Related Mortality in Patients with Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1061-1072.	4.5	7
43	Is a treat-to-target approach to lipid-lowering therapy appropriate in patients with chronic kidney disease? A prospective French cohort study. <i>Journal of Nephrology</i> , 2021, 34, 1467-1477.	2.0	3
44	Consequences of oral antithrombotic use in patients with chronic kidney disease. <i>Clinical and Translational Science</i> , 2021, 14, 2242-2253.	3.1	3
45	Decreased monocyte calcium sensing receptor expression in patients with chronic kidney disease is associated with impaired monocyte ability to reduce vascular calcification. <i>Kidney International</i> , 2021, 99, 1382-1391.	5.2	7
46	Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or without Anemia. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2020-2030.	6.1	37
47	Supplemented ERA-EDTA Registry data evaluated the frequency of dialysis, kidney transplantation, and comprehensive conservative management for patients with kidney failure in Europe. <i>Kidney International</i> , 2021, 100, 182-195.	5.2	31
48	A randomized multicenter trial on a lung ultrasound—guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk. <i>Kidney International</i> , 2021, 100, 1325-1333.	5.2	45
49	Heterogeneous neutralizing antibodies production after Sars-Cov2 vaccination in hemodialysis patients. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2616-2617.	2.9	0
50	Prescription of Direct Oral Anticoagulants to Patients With Moderate-to-Advanced CKD: Too Little or Just Right?. <i>Kidney International Reports</i> , 2021, 6, 2496-2500.	0.8	2
51	Uremic endothelial-derived extracellular vesicles: Mechanisms of formation and their role in cell adhesion, cell migration, inflammation, and oxidative stress. <i>Toxicology Letters</i> , 2021, 347, 12-22.	0.8	7
52	Can empathy be taught? A cross-sectional survey assessing training to deliver the diagnosis of end stage renal disease. <i>PLoS ONE</i> , 2021, 16, e0249956.	2.5	2
53	Syndecan-1 and Free Indoxyl Sulfate Levels Are Associated with miR-126 in Chronic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10549.	4.1	11
54	Adverse outcomes of proton pump inhibitors in patients with chronic kidney disease: The CKD—REIN cohort study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2967-2976.	2.4	17

#	ARTICLE	IF	CITATIONS
55	Pro-calcifying analysis of uraemic serum from patients treated with medium cut-off membrane in a prospective, cross-over study. CKJ: Clinical Kidney Journal, 2021, 14, 1798-1807.	2.9	5
56	A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology community. CKJ: Clinical Kidney Journal, 2021, 14, 23-35.	2.9	10
57	Effectiveness and Tolerance of Renin-Angiotensin System Inhibitors With Aging in Chronic Kidney Disease. Journal of the American Medical Directors Association, 2021, , .	2.5	1
58	Role of proteinuria in the anemia of chronic kidney disease. Kidney International, 2021, 100, 1160-1162.	5.2	5
59	Mild cognitive impairment and kidney disease: clinical aspects. Nephrology Dialysis Transplantation, 2020, 35, 10-17.	0.7	38
60	Young deceased donor kidneys show a survival benefit over older donor kidneys in transplant recipients aged 20â€“50â€“years: a study by the ERAâ€“EDTA Registry. Nephrology Dialysis Transplantation, 2020, 35, 534-543.	0.7	4
61	Changes in clinical indicators related to the transition from dialysis to kidney transplantationâ€”data from the ERA-EDTA Registry. CKJ: Clinical Kidney Journal, 2020, 13, 188-198.	2.9	1
62	Anemia and iron deficiency among chronic kidney disease Stages 3â€“5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated. CKJ: Clinical Kidney Journal, 2020, 13, 613-624.	2.9	68
63	Prevalence of atheromatous and non-atheromatous cardiovascular disease by age in chronic kidney disease. Nephrology Dialysis Transplantation, 2020, 35, 827-836.	0.7	23
64	Light chain only variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits is associated with a high detection rate of the pathogenic plasma cell clone. Kidney International, 2020, 97, 589-601.	5.2	32
65	Inflammation is an amplifier of lung congestion by high lv filling pressure in hemodialysis patients: a longitudinal study. Journal of Nephrology, 2020, 33, 583-590.	2.0	4
66	Survival of patients treated with extended-hours haemodialysis in Europe: an analysis of the ERA-EDTA Registry. Nephrology Dialysis Transplantation, 2020, 35, 488-495.	0.7	15
67	Vitamin K role in mineral and bone disorder of chronic kidney disease. Clinica Chimica Acta, 2020, 502, 66-72.	1.1	14
68	Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney International, 2020, 98, 1540-1548.	5.2	380
69	Practice patterns of dialysis access and outcomes in patients wait-listed early for kidney transplantation. BMC Nephrology, 2020, 21, 422.	1.8	3
70	Association between Uremic Toxin Concentrations and Bone Mineral Density after Kidney Transplantation. Toxins, 2020, 12, 715.	3.4	1
71	COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrology Dialysis Transplantation, 2020, 35, 1973-1983.	0.7	312
72	Urinary Sodium-to-Potassium Ratio and Blood Pressure in CKD. Kidney International Reports, 2020, 5, 1240-1250.	0.8	9

#	ARTICLE	IF	CITATIONS
73	MO072LONGITUDINAL SERUM BICARBONATE MEASUREMENTS AND RISK OF CHRONIC KIDNEY DISEASE PROGRESSION AND MORTALITY: INSIGHTS FROM THE CKD-REIN COHORT. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
74	Funding kidney research as a public health priority: challenges and opportunities. Nephrology Dialysis Transplantation, 2020, , .	0.7	6
75	Circulating Receptor Activator of Nuclear Factor kB Ligand and triglycerides are associated with progression of lower limb arterial calcification in type 2 diabetes: a prospective, observational cohort study. Cardiovascular Diabetology, 2020, 19, 140.	6.8	12
76	P0789SERUM URIC ACID IS ASSOCIATED WITH CHRONIC KIDNEY DISEASE PROGRESSION AND MORTALITY: INSIGHTS FROM THE CKD-REIN COHORT. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
77	Nephrology: achieving sustainability. Nephrology Dialysis Transplantation, 2020, 35, 2030-2033.	0.7	10
78	The Authors Reply. Kidney International Reports, 2020, 5, 2403-2404.	0.8	0
79	The COVID-19 outbreak and the angiotensin-converting enzyme 2: too little or too much?. Nephrology Dialysis Transplantation, 2020, 35, 1073-1075.	0.7	5
80	Quantification of free and protein bound uremic toxins in human serum by LC-MS/MS: Comparison of rapid equilibrium dialysis and ultrafiltration. Clinica Chimica Acta, 2020, 507, 228-235.	1.1	23
81	Indirect effects of severe acute respiratory syndrome coronavirus 2 on the kidney in coronavirus disease patients. CKJ: Clinical Kidney Journal, 2020, 13, 347-353.	2.9	34
82	Uremic Toxins and Vascular Dysfunction. Toxins, 2020, 12, 404.	3.4	37
83	A new player in the kidney's "bone axis: regulation of fibroblast growth factor-23 by renal glycerol-3-phosphate. Kidney International, 2020, 98, 1074-1076.	5.2	1
84	Difference in Profiles of the Gut-Derived Tryptophan Metabolite Indole Acetic Acid between Transplanted and Non-Transplanted Patients with Chronic Kidney Disease. International Journal of Molecular Sciences, 2020, 21, 2031.	4.1	17
85	Adverse Drug Reactions in Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1090-1102.	4.5	47
86	Data from the ERA-EDTA Registry were examined for trends in excess mortality in European adults on kidney replacement therapy. Kidney International, 2020, 98, 999-1008.	5.2	27
87	Inactive matrix gla protein plasma levels are associated with peripheral neuropathy in Type 2 diabetes. PLoS ONE, 2020, 15, e0229145.	2.5	9
88	Perceived Health and Quality of Life in Patients With CKD, Including Those With Kidney Failure: Findings From National Surveys in France. American Journal of Kidney Diseases, 2020, 75, 868-878.	1.9	56
89	Gut microbiota orchestrates PTH action in bone: role of butyrate and T cells. Kidney International, 2020, 98, 269-272.	5.2	5
90	Severe acute respiratory syndrome coronavirus 2 indirectly damages kidney structures. CKJ: Clinical Kidney Journal, 2020, 13, 1101-1104.	2.9	6

#	ARTICLE	IF	CITATIONS
91	Inhibition of miR-223 Expression Using a Sponge Strategy Decreases Restenosis in Rat Injured Carotids. <i>Current Vascular Pharmacology</i> , 2020, 18, 507-516.	1.7	9
92	Title is missing!. , 2020, 15, e0229145.		0
93	Title is missing!. , 2020, 15, e0229145.		0
94	Title is missing!. , 2020, 15, e0229145.		0
95	Title is missing!. , 2020, 15, e0229145.		0
96	The expanding roles of microRNAs in kidney pathophysiology. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 7-15.	0.7	30
97	Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry. <i>American Journal of Kidney Diseases</i> , 2019, 73, 184-193.	1.9	18
98	Acute kidney injury associated with lymphangitic carcinomatosis. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 527-529.	2.9	0
99	The nephrology crystal ball: the medium-term future. <i>Nephrology Dialysis Transplantation</i> , 2019, 35, 222-226.	0.7	2
100	International variation in the management of mineral bone disorder in patients with chronic kidney disease: Results from CKDopps. <i>Bone</i> , 2019, 129, 115058.	2.9	10
101	New Insights into the Roles of Monocytes/Macrophages in Cardiovascular Calcification Associated with Chronic Kidney Disease. <i>Toxins</i> , 2019, 11, 529.	3.4	37
102	Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1469-1480.	0.7	8
103	Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care. <i>Journal of Clinical Hypertension</i> , 2019, 21, 991-1001.	2.0	35
104	Does the Administration of Sevelamer or Nicotinamide Modify Uremic Toxins or Endotoxemia in Chronic Hemodialysis Patients?. <i>Drugs</i> , 2019, 79, 855-862.	10.9	11
105	Vascular calcification - any place left for nicotinamide?. <i>Nephrology Dialysis Transplantation</i> , 2019, 35, 18-22.	0.7	2
106	Endothelial Microparticles in Uremia: Biomarkers and Potential Therapeutic Targets. <i>Toxins</i> , 2019, 11, 267.	3.4	19
107	Serum concentration and vascular expression of adiponectin are differentially associated with the diabetic calcifying peripheral arteriopathy. <i>Diabetology and Metabolic Syndrome</i> , 2019, 11, 32.	2.7	8
108	The association between longer haemodialysis treatment times and hospitalization and mortality after the two-day break in individuals receiving three times a week haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1577-1584.	0.7	23

#	ARTICLE	IF	CITATIONS
109	Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients. <i>Scientific Reports</i> , 2019, 9, 4477.	3.3	62
110	Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1112-1114.	0.7	27
111	Reply to "Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate" by Stamp et al.. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1380-1381.	2.4	2
112	Guideline attainment and morbidity/mortality rates in a large cohort of European haemodialysis patients (EURODOPPS). <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 2105-2110.	0.7	11
113	Receptor for advanced glycation end products: a key molecule in the genesis of chronic kidney disease vascular calcification and a potential modulator of sodium phosphate co-transporter PIT-1 expression. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 2018-2030.	0.7	28
114	Sex Differences in Kidney Replacement Therapy Initiation and Maintenance. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1616-1625.	4.5	37
115	Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 269-280.	2.9	29
116	Evolution of protein-bound uremic toxins indoxyl sulphate and p-cresyl sulphate in acute kidney injury. <i>International Urology and Nephrology</i> , 2019, 51, 293-302.	1.4	25
117	International comparison of trends in patients commencing renal replacement therapy by primary renal disease. <i>Nephrology</i> , 2019, 24, 1064-1076.	1.6	11
118	Hyponatremia and MAPK kinase inhibitors in malignant melanoma: Frequency, pathophysiological aspects and clinical consequences. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 326-331.	3.3	5
119	<i>Lancet</i> Countdown paper: what does it mean for nephrology?. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 4-6.	0.7	4
120	Risk profile, quality of life and care of patients with moderate and advanced CKD: The French CKD-REIN Cohort Study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 277-286.	0.7	49
121	Changes in co-morbidity pattern in patients starting renal replacement therapy in Europe" data from the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1794-1804.	0.7	28
122	Factors associating with differences in the incidence of renal replacement therapy among elderly: data from the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1428-1435.	0.7	7
123	Access to kidney transplantation in European adults aged 75-84 years and related outcomes: an analysis of the European Renal Association-European Dialysis and Transplant Association Registry. <i>Transplant International</i> , 2018, 31, 540-553.	1.6	19
124	New insights into the key role of interleukin 6 in vascular calcification of chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 543-548.	0.7	43
125	Performance of an easy-to-use prediction model for renal patient survival: an external validation study using data from the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1786-1793.	0.7	3
126	Geographical Variations in Blood Pressure Level and Seasonality in Hemodialysis Patients. <i>Hypertension</i> , 2018, 71, 289-296.	2.7	24

#	ARTICLE	IF	CITATIONS
127	The European Renal Association â€œ European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2015: a summary. CKJ: Clinical Kidney Journal, 2018, 11, 108-122.	2.9	169
128	Exploring antibody-dependent adaptive immunity against aortic extracellular matrix components in experimental aortic aneurysms. Journal of Vascular Surgery, 2018, 68, 60S-71S.e3.	1.1	18
129	Magnesium supplementation: A consideration in dialysis patients. Seminars in Dialysis, 2018, 31, 11-14.	1.3	14
130	Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications. Clinical Research in Cardiology, 2018, 107, 214-221.	3.3	28
131	Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. Lancet Diabetes and Endocrinology,the, 2018, 6, 319-331.	11.4	102
132	The effect of differing kidney disease treatment modalities and organ donation and transplantation practices on health expenditure and patient outcomes. Nephrology Dialysis Transplantation, 2018, 33, 560-562.	0.7	15
133	Kidney transplant outcomes from older deceased donors: a paired kidney analysis by the European Renal Association-European Dialysis and Transplant Association Registry. Transplant International, 2018, 31, 708-719.	1.6	17
134	SP375UREMIC TOXINS ALTER ENDOTHELIAL CELL-TO-CELL JUNCTIONSâ€™ STRUCTURE. Nephrology Dialysis Transplantation, 2018, 33, i472-i473.	0.7	0
135	From old uraemic toxins to new uraemic toxins: place of â€œomicsâ€™. Nephrology Dialysis Transplantation, 2018, 33, iii2-iii5.	0.7	10
136	Chronic kidney failure mineral bone disorder leads to a permanent loss of hematopoietic stem cells through dysfunction of the stem cell niche. Scientific Reports, 2018, 8, 15385.	3.3	6
137	Lipid management in patients with chronic kidney disease. Nature Reviews Nephrology, 2018, 14, 727-749.	9.6	153
138	Uremia Impacts VE-Cadherin and ZO-1 Expression in Human Endothelial Cell-to-Cell Junctions. Toxins, 2018, 10, 404.	3.4	29
139	FP511TRENDS IN MORTALITY DUE TO MYOCARDIAL INFARCTION AND STROKE IN DIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2018, 33, i210-i210.	0.7	0
140	FP672BEYOND COMORBIDITY RELATED BARRIERS: FACTORS TO LIMIT THE ACCESS TO RRT MODALITIES AND CONSERVATIVE CARE. Nephrology Dialysis Transplantation, 2018, 33, i272-i272.	0.7	0
141	Magnesium as a Calcification Inhibitor. Advances in Chronic Kidney Disease, 2018, 25, 281-290.	1.4	22
142	Differential Determinants of Tubular Phosphate Reabsorption: Insights on Renal Excretion of Phosphates in Kidney Disease. American Journal of Nephrology, 2018, 47, 300-303.	3.1	3
143	A multi-omics analysis of the regulatory changes induced by miR-223 in a monocyte/macrophage cell line. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 2664-2678.	3.8	29
144	The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council. Nephrology Dialysis Transplantation, 2018, 33, 1077-1082.	0.7	4

#	ARTICLE	IF	CITATIONS
145	The Impact of Uremic Toxins on Cerebrovascular and Cognitive Disorders. <i>Toxins</i> , 2018, 10, 303.	3.4	61
146	The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 437-442.	2.9	1
147	The Impact of Uremic Toxins on Vascular Smooth Muscle Cell Function. <i>Toxins</i> , 2018, 10, 218.	3.4	74
148	Uremic Toxins and Clinical Outcomes: The Impact of Kidney Transplantation. <i>Toxins</i> , 2018, 10, 229.	3.4	24
149	Updates on the Mechanisms and the Care of Cardiovascular Calcification in Chronic Kidney Disease. <i>Seminars in Nephrology</i> , 2018, 38, 233-250.	1.6	53
150	Renal function markers and insulin sensitivity after 3 years in a healthy cohort, the EGIR-RISC study. <i>BMC Nephrology</i> , 2018, 19, 124.	1.8	0
151	Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohort. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2811-2823.	2.4	64
152	ERA-EDTA invests in transformation to greener health care. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 901-903.	0.7	21
153	Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw042.	0.7	47
154	Attainment of guideline targets in EURODOPPS haemodialysis patients: are differences related to a country's healthcare expenditure and nephrologist workforce?. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw409.	0.7	13
155	The measured glomerular filtration rate (mGFR) before and 6 months after bariatric surgery: A pilot study. <i>Nephrologie Et Therapeutique</i> , 2017, 13, 160-167.	0.5	14
156	Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease. <i>Journal of Nephrology</i> , 2017, 30, 629-634.	2.0	38
157	The systemic nature of CKD. <i>Nature Reviews Nephrology</i> , 2017, 13, 344-358.	9.6	265
158	Human Alternative Macrophages Populate Calcified Areas of Atherosclerotic Lesions and Display Impaired RANKL-Induced Osteoclastic Bone Resorption Activity. <i>Circulation Research</i> , 2017, 121, 19-30.	4.5	76
159	Acute Kidney Injury after Open Repair of Intact Abdominal Aortic Aneurysms. <i>Annals of Vascular Surgery</i> , 2017, 39, 294-300.	0.9	31
160	Free DNA precipitates calcium phosphate apatite crystals in the arterial wall in vivo. <i>Atherosclerosis</i> , 2017, 259, 60-67.	0.8	40
161	International differences in chronic kidney disease prevalence: a key public health and epidemiologic research issue. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, ii129-ii135.	0.7	31
162	Reducing major risk factors for chronic kidney disease. <i>Kidney International Supplements</i> , 2017, 7, 71-87.	14.2	155

#	ARTICLE	IF	CITATIONS
163	Strategies to improve monitoring disease progression, assessing cardiovascular risk, and defining prognostic biomarkers in chronic kidney disease. <i>Kidney International Supplements</i> , 2017, 7, 107-113.	14.2	19
164	Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1597-1597.	0.7	41
165	Chronic kidney disease. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17088.	30.5	558
166	Bone in CKD: why the ERA EDTA CKD-MBD working group organized a dedicated meeting?. <i>Journal of Nephrology</i> , 2017, 30, 621-622.	2.0	3
167	Vascular access conversion and patient outcome after hemodialysis initiation with a nonfunctional arteriovenous access: a prospective registry-based study. <i>BMC Nephrology</i> , 2017, 18, 74.	1.8	23
168	Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients. <i>Cardiovascular Diabetology</i> , 2017, 16, 24.	6.8	41
169	The role of phosphate in kidney disease. <i>Nature Reviews Nephrology</i> , 2017, 13, 27-38.	9.6	166
170	microRNAs in the pathophysiology of CKD-MBD: Biomarkers and innovative drugs. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 337-345.	3.8	48
171	Oxidized LDL, statin use, morbidity, and mortality in patients receiving maintenance hemodialysis. <i>Free Radical Research</i> , 2017, 51, 14-23.	3.3	9
172	Serum microRNAs are altered in various stages of chronic kidney disease: a preliminary study. <i>CKJ: Clinical Kidney Journal</i> , 2017, 10, 578-578.	2.9	14
173	Comment on Indoxyl Sulfateâ€”Review of Toxicity and Therapeutic Strategies. <i>Toxins</i> 2016, 8, 358. <i>Toxins</i> , 2017, 9, 142.	3.4	8
174	Predictors of nonfunctional arteriovenous access at hemodialysis initiation and timing of access creation: A registry-based study. <i>PLoS ONE</i> , 2017, 12, e0181254.	2.5	12
175	The European Renal Association â€” European Dialysis and Transplant Association Registry Annual Report 2014: a summary. <i>CKJ: Clinical Kidney Journal</i> , 2017, 10, 154-169.	2.9	64
176	Obesity and access to kidney transplantation in patients starting dialysis: A prospective cohort study. <i>PLoS ONE</i> , 2017, 12, e0176616.	2.5	36
177	MP284CHRONIC RENAL FAILURE WORSENS ISCHEMIC STROKE SEVERITY AND NEUROLOGICAL CONSEQUENCES IN MICE. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i433-i433.	0.7	0
178	N-methyl-2-pyridone-5-carboxamide (2PY)â€”Major Metabolite of Nicotinamide: An Update on an Old Uremic Toxin. <i>Toxins</i> , 2016, 8, 339.	3.4	42
179	The mir-221/222 Cluster is a Key Player in Vascular Biology via the Fine-Tuning of Endothelial Cell Physiology. <i>Current Vascular Pharmacology</i> , 2016, 15, 40-46.	1.7	41
180	Magnesium Attenuates Phosphate-Induced Deregulation of a MicroRNA Signature and Prevents Modulation of Smad1 and Osterix during the Course of Vascular Calcification. <i>BioMed Research International</i> , 2016, 2016, 1-11.	1.9	51

#	ARTICLE	IF	CITATIONS
181	MO054MORTALITY AND MAJOR CARDIOVASCULAR EVENTS ASSOCIATED WITH BLOOD PRESSURE CONTROL AND CHRONIC KIDNEY DISEASE IN THE ELDERLY. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i53-i53.	0.7	0
182	MP002TUMOR NECROSIS FACTOR-LIKE WEAK INDUCER OF APOPTOSIS FAVORS PHOSPHATE-INDUCED CALCIFICATION OF VASCULAR SMOOTH MUSCLE CELLS. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i344-i344.	0.7	0
183	Empathy and stress in nurses working in haemodialysis: a qualitative study. <i>Journal of Advanced Nursing</i> , 2016, 72, 1075-1085.	3.3	22
184	Reconsidering the Lack of Urea Toxicity in Dialysis Patients. <i>Seminars in Dialysis</i> , 2016, 29, 333-337.	1.3	21
185	Magnesium-based interventions for normal kidney function and chronic kidney disease. <i>Magnesium Research</i> , 2016, 29, 126-140.	0.5	18
186	Protein-bound toxins: has the Cinderella of uraemic toxins turned into a princess?. <i>Clinical Science</i> , 2016, 130, 2209-2216.	4.3	15
187	Activin receptor IIA ligand trap in chronic kidney disease: 1 drug to prevent 2 complications or even more?. <i>Kidney International</i> , 2016, 89, 1180-1182.	5.2	4
188	The CKD Outcomes and Practice Patterns Study (CKDopps): Rationale and Methods. <i>American Journal of Kidney Diseases</i> , 2016, 68, 402-413.	1.9	47
189	Clinical management of the uraemic syndrome in chronic kidney disease. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 360-373.	11.4	78
190	Intestinal metabolites, chronic kidney disease and renal transplantation: Enigma Variations?. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1547-1551.	0.7	11
191	Drug-coated balloon angioplasty for dialysis access fistula stenosis. <i>Seminars in Vascular Surgery</i> , 2016, 29, 178-185.	2.8	17
192	Efficacy of a remote web-based lung ultrasound training for nephrologists and cardiologists: a LUST trial sub-project. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1982-1988.	0.7	60
193	The Agreement between Auscultation and Lung Ultrasound in Hemodialysis Patients: The LUST Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 2005-2011.	4.5	124
194	Levels of Indoxyl Sulfate in Kidney Transplant Patients, and the Relationship With Hard Outcomes. <i>Circulation Journal</i> , 2016, 80, 722-730.	1.6	28
195	Serum microRNAs are altered in various stages of chronic kidney disease: a preliminary study. <i>CKJ: Clinical Kidney Journal</i> , 2016, 10, sfw060.	2.9	14
196	SO037ANEMIA PREVALENCE AND TREATMENT AMONG PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 3-5: DATA FROM THE CHRONIC KIDNEY DISEASE OUTCOMES AND PRACTICE PATTERNS STUDY (CKDOPPS). <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i16-i17.	0.7	5
197	Renal replacement therapy in Europe: a summary of the 2013 ERA-EDTA Registry Annual Report with a focus on diabetes mellitus. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 457-469.	2.9	70
198	Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis?. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1211-1219.	0.7	52

#	ARTICLE	IF	CITATIONS
199	Changing bone patterns with progression of chronic kidney disease. <i>Kidney International</i> , 2016, 89, 289-302.	5.2	143
200	Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 337-348.	0.7	206
201	Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target. <i>American Journal of Kidney Diseases</i> , 2016, 67, 483-498.	1.9	271
202	Neurological complications in chronic kidney disease patients. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1606-1614.	0.7	54
203	Uremic Toxicity of Advanced Glycation End Products in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 354-370.	6.1	175
204	Paraformaldehyde sulfate acutely impairs vascular reactivity and induces vascular remodeling. <i>Journal of Cellular Physiology</i> , 2015, 230, 2927-2935.	4.1	57
205	The Addition of Vascular Calcification Scores to Traditional Risk Factors Improves Cardiovascular Risk Assessment in Patients with Chronic Kidney Disease. <i>PLoS ONE</i> , 2015, 10, e0131707.	2.5	35
206	miR-126 Is Involved in Vascular Remodeling under Laminar Shear Stress. <i>BioMed Research International</i> , 2015, 2015, 1-11.	1.9	55
207	The fate of triaged and rejected manuscripts. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1947-1950.	0.7	9
208	Pro: Cardiovascular calcifications are clinically relevant. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 345-351.	0.7	53
209	Distinct Effects of Inorganic Phosphate on Cell Cycle and Apoptosis in Human Vascular Smooth Muscle Cells. <i>Journal of Cellular Physiology</i> , 2015, 230, 347-355.	4.1	26
210	Magnesium and cardiovascular complications of chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2015, 11, 432-442.	9.6	62
211	Opponent's comments. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 357-357.	0.7	6
212	Peritoneal Delivery of Sodium Pyrophosphate Blocks the Progression of Pre-existing Vascular Calcification in Uremic Apolipoprotein-E Knockout Mice. <i>Calcified Tissue International</i> , 2015, 97, 179-192.	3.1	14
213	MicroRNA deregulation in symptomatic carotid plaque. <i>Journal of Vascular Surgery</i> , 2015, 62, 1245-1250.e1.	1.1	75
214	The double challenge of resistant hypertension and chronic kidney disease. <i>Lancet, The</i> , 2015, 386, 1588-1598.	13.7	147
215	High inorganic phosphate concentration inhibits osteoclastogenesis by modulating miR-223. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015, 1852, 2202-2212.	3.8	46
216	Deleterious vascular effects of indoxyl sulfate and reversal by oral adsorbent AST-120. <i>Atherosclerosis</i> , 2015, 243, 248-256.	0.8	46

#	ARTICLE	IF	CITATIONS
217	Association between indoxyl sulfate and bone histomorphometry in pre-dialysis chronic kidney disease patients. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2014, 36, 289-96.	0.9	42
218	microRNAs are dysregulated in the cerebral microvasculature of CKD mice. <i>Frontiers in Bioscience - Elite</i> , 2014, E6, 80-88.	1.8	20
219	The French Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort study. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1500-1507.	0.7	81
220	The Author Replies:. <i>Kidney International</i> , 2014, 85, 712.	5.2	0
221	Differential Effects of Indoxyl Sulfate and Inorganic Phosphate in a Murine Cerebral Endothelial Cell Line (bEnd.3). <i>Toxins</i> , 2014, 6, 1742-1760.	3.4	45
222	Calcium-Sensing Receptor Activation in Chronic Kidney Disease: Effects Beyond Parathyroid Hormone Control. <i>Seminars in Nephrology</i> , 2014, 34, 648-659.	1.6	20
223	The Role of Klotho on Vascular Calcification and Endothelial Function in Chronic Kidney Disease. <i>Seminars in Nephrology</i> , 2014, 34, 578-585.	1.6	42
224	New Insights Into the FGF23-Klotho Axis. <i>Seminars in Nephrology</i> , 2014, 34, 586-597.	1.6	73
225	Calcimimetics increase CaSR expression and reduce mineralization in vascular smooth muscle cells: mechanisms of action. <i>Cardiovascular Research</i> , 2014, 101, 256-265.	3.8	67
226	Possible involvement of microRNAs in vascular damage in experimental chronic kidney disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 88-98.	3.8	66
227	Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario?. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1275-1284.	0.7	50
228	Uremic toxicity and sclerostin in chronic kidney disease patients. <i>Nephrologie Et Therapeutique</i> , 2014, 10, 463-470.	0.5	71
229	Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1815-1820.	0.7	103
230	The role of lipids and uremic toxins in cardiovascular disease in CKD. <i>Clinical and Experimental Nephrology</i> , 2014, 18, 255-256.	1.6	7
231	Vascular calcification in patients with type 2 diabetes: the involvement of matrix Gla protein. <i>Cardiovascular Diabetology</i> , 2014, 13, 85.	6.8	65
232	Clinical Studies and Chronic Kidney Disease: What Did we Learn Recently?. <i>Seminars in Nephrology</i> , 2014, 34, 164-179.	1.6	20
233	Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 427-436.	11.4	125
234	Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. <i>Lancet</i> , 2014, 383, 1831-1843.	13.7	341

#	ARTICLE	IF	CITATIONS
235	miR-223: An inflammatory oncomiR enters the cardiovascular field. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 1001-1009.	3.8	147
236	Vascular Toxicity of Phosphate in Chronic Kidney Disease. <i>Circulation Journal</i> , 2014, 78, 2339-2346.	1.6	53
237	Use of Nicotinamide to Treat Hyperphosphatemia in Dialysis Patients. <i>Drugs in R and D</i> , 2013, 13, 165-173.	2.2	29
238	Farnesyltransferase inhibitor R115777 protects against vascular disease in uremic mice. <i>Atherosclerosis</i> , 2013, 229, 42-51.	0.8	16
239	Chronic renal failure does not affect the mouse locomotor activity in darkness conditions. <i>Biological Rhythm Research</i> , 2013, 44, 771-777.	0.9	1
240	Cognitive Disorders and Dementia in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 353-363.	6.1	438
241	LDL cholesterol in CKD "to treat or not to treat?". <i>Kidney International</i> , 2013, 84, 451-456.	5.2	49
242	Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 869-878.	0.7	154
243	The clinical impact of plasma leptin levels in a cohort of chronic kidney disease patients. <i>CKJ: Clinical Kidney Journal</i> , 2013, 6, 63-70.	2.9	16
244	Vascular calcification in chronic kidney disease: a review. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2013, 35, 147-161.	0.9	27
245	Does P-Cresylglucuronide Have the Same Impact on Mortality as Other Protein-Bound Uremic Toxins?. <i>PLoS ONE</i> , 2013, 8, e67168.	2.5	60
246	Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival. <i>CKJ: Clinical Kidney Journal</i> , 2012, 5, i52-i61.	2.9	77
247	Indoxyl sulphate inhibits osteoclast differentiation and function. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2176-2181.	0.7	79
248	Effects of phosphate on vascular function under normal conditions and influence of the uraemic state. <i>Cardiovascular Research</i> , 2012, 96, 130-139.	3.8	79
249	Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 505-513.	0.7	50
250	Upregulation of BAD, a pro-apoptotic protein of the BCL2 family, in vascular smooth muscle cells exposed to uremic conditions. <i>Biochemical and Biophysical Research Communications</i> , 2012, 417, 479-483.	2.1	34
251	Inorganic Phosphate Accelerates the Migration of Vascular Smooth Muscle Cells: Evidence for the Involvement of miR-223. <i>PLoS ONE</i> , 2012, 7, e47807.	2.5	105
252	Monocyte subpopulations and cardiovascular risk in chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2012, 8, 362-369.	9.6	143

#	ARTICLE	IF	CITATIONS
253	Symmetric Dimethylarginine as a Proinflammatory Agent in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2374-2383.	4.5	119
254	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. <i>Lancet</i> , The, 2011, 377, 2181-2192.	13.7	2,087
255	Uremic Toxin Indoxyl Sulfate Inhibits Human Vascular Smooth Muscle Cell Proliferation. <i>Therapeutic Apheresis and Dialysis</i> , 2011, 15, 135-139.	0.9	24
256	Estimated Glomerular Filtration Rate Is a Poor Predictor of Concentration for a Broad Range of Uremic Toxins. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1266-1273.	4.5	79
257	Guanidino Compounds as Cause of Cardiovascular Damage in Chronic Kidney Disease: An in vitro Evaluation. <i>Blood Purification</i> , 2010, 30, 277-287.	1.8	49
258	The Circulating Inactive Form of Matrix Gla Protein Is a Surrogate Marker for Vascular Calcification in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 568-575.	4.5	251
259	Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1183-1191.	0.7	371
260	Atherosclerosis in CKD: differences from the general population. <i>Nature Reviews Nephrology</i> , 2010, 6, 723-735.	9.6	174
261	Oxidized low density lipoprotein decreases Rankl-induced differentiation of osteoclasts by inhibition of Rankl signaling. <i>Journal of Cellular Physiology</i> , 2009, 221, 572-578.	4.1	35
262	The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE ^{-/-}) mice. <i>Atherosclerosis</i> , 2009, 205, 55-62.	0.8	101
263	Serum Indoxyl Sulfate Is Associated with Vascular Disease and Mortality in Chronic Kidney Disease Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1551-1558.	4.5	740
264	High extracellular inorganic phosphate concentration inhibits RANKL signaling in osteoclast-like cells. <i>Journal of Cellular Physiology</i> , 2008, 215, 47-54.	4.1	103
265	Effect of Simvastatin in Apolipoprotein E Deficient Mice With Surgically Induced Chronic Renal Failure. <i>Journal of Urology</i> , 2008, 179, 1631-1636.	0.4	27
266	Sevelamer Prevents Uremia-Enhanced Atherosclerosis Progression in Apolipoprotein E Deficient Mice. <i>Circulation</i> , 2005, 112, 2875-2882.	1.6	139
267	Vascular calcification in chronic kidney disease. <i>American Journal of Kidney Diseases</i> , 2004, 43, 572-579.	1.9	381
268	Review on uremic toxins: Classification, concentration, and interindividual variability. <i>Kidney International</i> , 2003, 63, 1934-1943.	5.2	1,379
269	Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 335-340.	0.7	207
270	Lipid-lowering therapy in patients with renal disease. <i>Kidney International</i> , 1995, 48, 188-198.	5.2	118

#	ARTICLE	IF	CITATIONS
271	Glomerulonephritis with non-Randall-type, non-cryoglobulinemic monoclonal immunoglobulin G deposits [PGNMID and ITC]. CKJ: Clinical Kidney Journal, 0, , .	2.9	0